FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034760164> ?p ?o ?g. }

• W2034760164 endingPage "278" @default.
• W2034760164 startingPage "273" @default.
• W2034760164 abstract "Sensory neuropathy is a common adverse effect of the nucleoside analogue anti-retroviral drugs didanosine (ddl) and stauvudine (d4T). These drugs are increasingly being used in combination, and it is not currently known whether the incidence of neuropathy is higher with combination compared to individual drug use. It is also not known if hydroxyurea, used to potentiate the antiviral efficacy of these drugs, may also increase the risk of neuropathy. The purpose of this analysis is to investigate if the combination of ddl and d4T, with or without hydroxyurea, has a higher incidence of neuropathy than a single drug regimen.Data were obtained from patients followed longitudinally by the Johns Hopkins AIDS Services. Incidence rates of development of neuropathy were calculated for each of five regimens: ddl (+/- hydroxyurea), ddl + d4T (+/- hydroxyurea), and d4T. Cox proportional hazard regression was used to compare the relative risk of neuropathy for each regimen adjusting for CD4 cell count, other drugs received, and time on therapy.A total of 1116 patients received at least one of the five regimens. There were 117 cases of neuropathy. The crude incidence rate of neuropathy ranged from 6.8 cases per 100 person-years for ddl to 28.6 cases per 100 person-years for ddl + d4T + hydroxyurea. Compared with ddl alone, and adjusting for CD4 cell counts and other variables, the relative risk of neuropathy was 1.39 [95% confidence interval (CI): 0.84-2.32] for d4T alone, 2.35 (95% CI: 0.69-8.07) for ddl + hydroxyurea, 3.50 (95% CI: 1.81-6.77) for ddl + d4T, and 7.80 (95% CI: 3.92-15.5) for ddl + d4T + hydroxyurea.Based on the data, the risk of neuropathy is additive or even synergistic for ddl + d4T + hydroxyurea compared with ddl or d4T alone. The combination of ddl + d4T also increases the risk of neuropathy but less than when hydroxyurea is included." @default.
• W2034760164 created "2016-06-24" @default.
• W2034760164 creator A5038368249 @default.
• W2034760164 creator A5064199515 @default.
• W2034760164 creator A5069032071 @default.
• W2034760164 creator A5074418085 @default.
• W2034760164 date "2000-02-01" @default.
• W2034760164 modified "2023-10-10" @default.
• W2034760164 title "Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea" @default.
• W2034760164 cites W1989206970 @default.
• W2034760164 cites W1990260752 @default.
• W2034760164 cites W1999945695 @default.
• W2034760164 cites W2036738390 @default.
• W2034760164 cites W2047890674 @default.
• W2034760164 cites W2058563502 @default.
• W2034760164 cites W2065387844 @default.
• W2034760164 cites W2081340557 @default.
• W2034760164 cites W2084890679 @default.
• W2034760164 cites W2140121783 @default.
• W2034760164 cites W4239667773 @default.
• W2034760164 doi "https://doi.org/10.1097/00002030-200002180-00009" @default.
• W2034760164 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10716503" @default.
• W2034760164 hasPublicationYear "2000" @default.
• W2034760164 type Work @default.
• W2034760164 sameAs 2034760164 @default.
• W2034760164 citedByCount "181" @default.
• W2034760164 countsByYear W20347601642012 @default.
• W2034760164 countsByYear W20347601642013 @default.
• W2034760164 countsByYear W20347601642014 @default.
• W2034760164 countsByYear W20347601642015 @default.
• W2034760164 countsByYear W20347601642016 @default.
• W2034760164 countsByYear W20347601642017 @default.
• W2034760164 countsByYear W20347601642020 @default.
• W2034760164 countsByYear W20347601642021 @default.
• W2034760164 countsByYear W20347601642022 @default.
• W2034760164 crossrefType "journal-article" @default.
• W2034760164 hasAuthorship W2034760164A5038368249 @default.
• W2034760164 hasAuthorship W2034760164A5064199515 @default.
• W2034760164 hasAuthorship W2034760164A5069032071 @default.
• W2034760164 hasAuthorship W2034760164A5074418085 @default.
• W2034760164 hasBestOaLocation W20347601641 @default.
• W2034760164 hasConcept C120665830 @default.
• W2034760164 hasConcept C121332964 @default.
• W2034760164 hasConcept C126322002 @default.
• W2034760164 hasConcept C134018914 @default.
• W2034760164 hasConcept C141071460 @default.
• W2034760164 hasConcept C197934379 @default.
• W2034760164 hasConcept C203014093 @default.
• W2034760164 hasConcept C207103383 @default.
• W2034760164 hasConcept C2776543447 @default.
• W2034760164 hasConcept C2776694085 @default.
• W2034760164 hasConcept C2777333352 @default.
• W2034760164 hasConcept C2777447569 @default.
• W2034760164 hasConcept C2779316324 @default.
• W2034760164 hasConcept C2779889181 @default.
• W2034760164 hasConcept C2779901536 @default.
• W2034760164 hasConcept C2780216070 @default.
• W2034760164 hasConcept C2780727368 @default.
• W2034760164 hasConcept C2781413609 @default.
• W2034760164 hasConcept C3013748606 @default.
• W2034760164 hasConcept C44249647 @default.
• W2034760164 hasConcept C55493867 @default.
• W2034760164 hasConcept C555293320 @default.
• W2034760164 hasConcept C61511704 @default.
• W2034760164 hasConcept C71924100 @default.
• W2034760164 hasConcept C86803240 @default.
• W2034760164 hasConcept C90924648 @default.
• W2034760164 hasConceptScore W2034760164C120665830 @default.
• W2034760164 hasConceptScore W2034760164C121332964 @default.
• W2034760164 hasConceptScore W2034760164C126322002 @default.
• W2034760164 hasConceptScore W2034760164C134018914 @default.
• W2034760164 hasConceptScore W2034760164C141071460 @default.
• W2034760164 hasConceptScore W2034760164C197934379 @default.
• W2034760164 hasConceptScore W2034760164C203014093 @default.
• W2034760164 hasConceptScore W2034760164C207103383 @default.
• W2034760164 hasConceptScore W2034760164C2776543447 @default.
• W2034760164 hasConceptScore W2034760164C2776694085 @default.
• W2034760164 hasConceptScore W2034760164C2777333352 @default.
• W2034760164 hasConceptScore W2034760164C2777447569 @default.
• W2034760164 hasConceptScore W2034760164C2779316324 @default.
• W2034760164 hasConceptScore W2034760164C2779889181 @default.
• W2034760164 hasConceptScore W2034760164C2779901536 @default.
• W2034760164 hasConceptScore W2034760164C2780216070 @default.
• W2034760164 hasConceptScore W2034760164C2780727368 @default.
• W2034760164 hasConceptScore W2034760164C2781413609 @default.
• W2034760164 hasConceptScore W2034760164C3013748606 @default.
• W2034760164 hasConceptScore W2034760164C44249647 @default.
• W2034760164 hasConceptScore W2034760164C55493867 @default.
• W2034760164 hasConceptScore W2034760164C555293320 @default.
• W2034760164 hasConceptScore W2034760164C61511704 @default.
• W2034760164 hasConceptScore W2034760164C71924100 @default.
• W2034760164 hasConceptScore W2034760164C86803240 @default.
• W2034760164 hasConceptScore W2034760164C90924648 @default.
• W2034760164 hasIssue "3" @default.
• W2034760164 hasLocation W20347601641 @default.
• W2034760164 hasLocation W20347601642 @default.
• W2034760164 hasLocation W20347601643 @default.
• W2034760164 hasOpenAccess W2034760164 @default.

• next